-

07:26:42 PM

RAIN Stock News

RAIN - Rain Therapeutics Inc

11/22/21 10:05 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Present at Upcoming Investor Conferences

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside

RHEA-AI

neutral

11/19/21 8:00 AM

Nasdaq : RAIN

clinical triallow float

Rain Therapeutics Doses First Patient in Phase 2 Basket Trial of Milademetan for MDM2-Amplified Advanced Solid Tumors (MANTRA-2)

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company

RHEA-AI

neutral

11/10/21 8:00 AM

Nasdaq : RAIN

earningslow float

Rain Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Progress

New Phase 2 clinical trial planned for milademetan in Merkel cell carcinoma (MCC), the MANTRA-3 trial, to start in mid-2022 Quarter-end cash position of $150.1 million provides runway to advance research and development (R&D) pipeline and complete all three planned clinical trials of milademetan

RHEA-AI

neutral

11/09/21 8:00 AM

Nasdaq : RAIN

clinical triallow float

Rain Therapeutics Plans Phase 2 Merkel Cell Carcinoma Clinical Trial (MANTRA-3) of Milademetan

The Merkel cell trial will be prioritized over the previously planned Phase 2 trial in patients with intimal sarcoma, and will evaluate milademetan in patients with IO-refractory disease Rain to host first annual research and development (R&D) day at 11am EST today NEWARK, Calif., Nov. 09, 2021

RHEA-AI

neutral

11/03/21 8:00 AM

Nasdaq : RAIN

conferencesearningslow float

Rain Therapeutics to Report Third Quarter 2021 Financial Results and Highlights of Recent Progress on November 10, 2021

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced it will report financial results for the third quarter that ended September 30, 2021 and highlights of recent

RHEA-AI

neutral

10/25/21 8:00 AM

Nasdaq : RAIN

low float

Rain Therapeutics Hosting Research and Development (R&D) Day

Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that it will host a virtual Research and Development (R&D) day on Tuesday,

RHEA-AI

neutral

10/07/21 10:00 AM

Nasdaq : RAIN

low float

Rain Therapeutics Presents Data on Milademetan (RAIN-32) at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a

RHEA-AI

neutral

10/04/21 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Present on Milademetan at the 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Rain Therapeutics Inc., (NasdaqGS: RAIN), (“Rain”), a late-stage company developing

RHEA-AI

neutral

09/22/21 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the Cantor

RHEA-AI

neutral

09/09/21 8:00 AM

Nasdaq : RAIN

conferenceslow float

Rain Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Rain Therapeutics Inc. (NasdaqGS: RAIN) (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will present at the H.C.

RHEA-AI

neutral

RAIN Data:

IndustryMedicinal and Botanical Manufacturing
Websitewww.rainthera.com
Security nameRain Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834

RAIN Description:

Rain Therapeutics Inc. is a clinical-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, RAIN-32 (milademetan, formerly known as DS-3032), is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to RAIN-32, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.